癌症·新知：科学终结恐慌

AN S J, CHEN Z H, Su J, et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status[J]. PloS one 7,2012:e40109.
ANGELO M G, ZIMA J, TAvARES DA SILvA F, et al. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience[J].Pharmacoepidemiology and drug safety,2014,23:456-465.
ASAKA M, MABE K. Strategies for eliminating death from gastric cancer in Japan. Proceedings of the Japan Academy Series B[J].Physical and biological sciences,2014,90:251-258.
BADALIAN-vERy G, vERGILIO J A, DEGAR B A, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis[J]. Blood, 2010,116:1919-1923.
BAJPAI R, MATuLIS S M, WEI C, et al. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax[J]. Oncogene,2016,35:3955-3964.
BALACHANDRAN v P, CAvNAR M J, ZENG S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido[J]. Nature medicine ,2011,17:1094-1100.
BATE-EyA L T, DEN HARTOG I J, vAN DER PLOEG I, et al. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition[J]. Oncotarget, 2016,7: 27946-27958.
BEDI G, CARRILLO F, CECCHI G A, et al. Automated analysis of free speech predicts psychosis onset in high-risk youths[J]. NPJ schizophrenia,2015,1:15030.
BEDNARCZyK R A, DAvIS R, AuLT K, et al. Sexual activity-related outcomes after human papillomavirus vaccination of 11- to 12-year-olds[J]. Pediatrics, 2012,130:798-805.
BERNSTEIN M B, KRISHNAN S, HODGE J W, et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? [J]. Nature reviews Clinical oncology,2016,13:516-524.
BEZu L, GOMES-DE-SILvA L C, DEWITTE H, et al. Combinatorial strategies for the induction of immunogenic cell death[J]. Frontiers in immunology, 2015,6: 187.
BONA C, BOT A. The 2011 Nobel Prize--honoring the memory of Dr. Ralph Steinman[J].International reviews of immunology, 2011,30:233-234.
BOSETTI C, MALvEZZI M, CHATENOuD L, et al. Trends in cancer mortality in the Americas, 1970-2000[J]. Annals of oncology , 2005,16:489-511.
BOuTROS C, TARHINI A, ROuTIER E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination[J]. Nature reviews Clinical oncology, 2016,13: 473-486.
BOyLE G M, D’SOuZA M M, PIERCE C J, et al. Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse models[J].PloS one 9,2014: e108887.
BOyMAN O, SPRENT J. The role of interleukin-2 during homeostasis and activation of the immune system[J]. Nature reviews Immunology, 2012,12: 180-190.
BuCHBINDER R, OSBORNE R H, EBELING P R, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures[J]. The New England journal of medicine,2009,361:557-568.
CARDOSO F, vAN’T vEER L J, BOGAERTS J, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer[J]. The New England journal of medicine,2016,375: 717-729.
CASTELLSAGuE X, SCHNEIDER A, KAuFMANN A M, et al. HPv vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives[J].Gynecologic oncology, 2009,115: S15-23.
Centers for Disease and Prevention.Annual smoking-attributable mortality, years of potential life lost, and productivity losses--united States, 1997-2001[J]. MMWR Morbidity and mortality weekly report,2005,54:625-628.
CHAO M, Wu H, JIN K, et al. A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis[J]. eLife , 2016,5.
CHEN G Q, ZHu J, SHI X G, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia: As₂O₃ induces NB4 cell apoptosis with downregulation of BCL-2 expression and modulation of PML-RAR alpha/PML proteins[J]. Blood, 1996,88:1052-1061.
CHEN M, CHANG C H, TAO L, et al. Residential Exposure to Pesticide During Childhood and Childhood Cancers: A Meta-Analysis[J]. Pediatrics , 2015a,136:719-729.
CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA: a cancer journal for clinicians, 2016,66:115-132.
CHEN Z, PETO R, ZHOu M, et al. Contrasting male and female trends in tobacco-attributed mortality in China: evidence from successive nationwide prospective cohort studies[J]. Lancet ,2015b,386:1447-1456.
CHIOu v L, BuROTTO M. Pseudoprogression and Immune-Related Response in Solid Tumors[J]Journal of clinical oncology , 2015,33:3541-3543.
COyNE G O, TAKEBE N, CHEN A P. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH[J]. Current problems in cancer, 2017, S0147-0272 (17) 30016-30018.CuRTIN J A, FRIDLyAND J, KAGESHITA T, et al. Distinct sets of genetic alterations in melanoma[J]. The New England journal of medicine , 2005,353: 2135-2147.
DE LEON J. Atypical antipsychotic dosing: the effect of smoking and caffeine[J]. Psychiatric services, 2004,55: 491-493.
DEvITA v T, CHu E. A history of cancer chemotherapy[J]. Cancer research, 2008,68: 8643-8653.DO K, O’SuLLIvAN COyNE G, CHEN A P. An overview of the NCI precision medicine trials-NCI MATCH and MPACT[J]. Chinese clinical oncology, 2015,4:31.
DuNN G P, OLD L J, SCHREIBER R D. The three Es of cancer immunoediting[J]. Annual review of immunology, 2004,22:329-360.
EMENS L A, MIDDLETON G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies[J]. Cancer immunology research, 2015,3:436-443.
FREDERICK D T, PIRIS A, COGDILL A P, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma[J]. Clinical cancer research, 2013,19:1225-1231.
FREISE K J, JONES A K, ECKERT D, et al. Impact of venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia[J]. Clinical pharmacokinetics, 2017,56:515-523.
GAFFEN S L, LIu K D. Overview of interleukin-2 function, production and clinical applications[J]. Cytokine, 2004,28: 109-123.
GALMARINI D, GALMARINI C M, GALMARINI F C. Cancer chemotherapy: a critical analysis of its 60 years of history[J]. Critical reviews in oncology/hematology, 2012,84:181-199.
GAMBACORTI-PASSERINI C, ANTOLINI L, MAHON F X, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib[J]. Journal of the National Cancer Institute , 2011,103:553-561.
GOLDEN E B, APETOH L. Radiotherapy and immunogenic cell death[J]. Seminars in radiation oncology , 2015,25,11-17.
GOTO E, TOMITA A, HAyAKAWA F, et al. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment[J]. Blood, 2011,118:1600-1609.
GROvE W M, ZALD D H, LEBOW B S, et al. Clinical versus mechanical prediction: a metaanalysis[J]. Psychological assessment, 2000,12:19-30.
HA S y, CHOI S J, CHO J H, et al. Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR[J]. Oncotarget, 2015,6: 5465-5474.
HE J, ZHANG X, WEI y, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus[J]. Nature medicine, 2016,22:991-993.
HERN W M. Has the human species become a cancer on the planet? A theoretical view of population growth as a sign of pathology[J]. Current world leaders , 1993,36(1):89-124.
HODI F S, O’DAy S J, MCDERMOTT D F, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. The New England journal of medicine, 2010,363: 711-723.
HORIKAWA N, yAMAZAKI T, SAGAWA M, et al. The disclosure of information to cancer patients and its relationship to their mental state in a consultation-liaison psychiatry setting in Japan[J].General hospital psychiatry , 1999,21:368-373.
HOSAKA T, AWAZu H, FuKuNISHI I, et al. Disclosure of true diagnosis in Japanese cancer patients[J]. General hospital psychiatry, 1999,21:209-213.
HOuGHTON S C, REEvES K W, HANKINSON S E, et al. Perineal powder use and risk of ovarian cancer[J]. Journal of the National Cancer Institute , 2014,106.
HOWICK J, BISHOP F L, HENEGHAN C, et al. Placebo use in the united kingdom: results from a national survey of primary care practitioners[J]. PloS one, 2013,8:e58247.
Hu J, LIu y F, Wu C, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia[J]. Proceedings of the National Academy of Sciences of the united States of America, 2009,106:3342-3347.
HuANG H L, CHENG S y, yAO C A. Truth Telling and Treatment Strategies in End-of-Life Care in Physician-Led Accountable Care Organizations: Discrepancies Between Patients’ Preferences and Physicians’ Perceptions[J]. Medicine, 2015,94: e657.
HuANG H y, SHI J F, GuO L W, et al. Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China: a hospital-based, multicenter, cross-sectional survey[J].Chinese journal of cancer, 2017,36,41.
HuGHES P E, CAENEPEEL S, Wu L C. Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer[J]. Trends in immunology , 2016,37:462-476.
HuH J R, GuO M, HAy B A. Compensatory proliferation induced by cell death in the Drosophila wing disc requires activity of the apical cell death caspase Dronc in a nonapoptotic role[J].Current biology , 2004, CB 14:1262-1266.
HyMAN D M, PuZANOv I, SuBBIAH v, et al. vemurafenib in Multiple Nonmelanoma Cancers with BRAF v600 Mutations[J]. The New England journal of medicine, 2015,373:726-736.
ITO T, ANDO H, SuZuKI T. Identification of a primary target of thalidomide teratogenicity[J].Science , 2010,327:1345-1350.
IyER G, HANRAHAN A J, MILOWSKy M I, et al. Genome sequencing identifies a basis for everolimus sensitivity[J]. Science , 2012,338:221.
JEMAL A, SIEGEL R, Xu J, et al. Cancer statistics, 2010[J]. CA, 2010,60:277-300.
JOOSSENS J v, HILL M J, ELLIOTT P, et al. Dietary salt, nitrate and stomach cancer mortality in 24 countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative Research Group[J]. International journal of epidemiology, 1996,25: 494-504.
KALLMES D F, COMSTOCK B A, HEAGERTy P J, et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures[J]. The New England journal of medicine, 2009,361:569-579.
KAZDAGLIS G A, ARNAOuTOGLOu C, KARyPIDIS D, et al. Disclosing the truth to terminal cancer patients: a discussion of ethical and cultural issues[J]. Eastern Mediterranean health journal ,2010,16:442-447.
KHAW S L, SuRyANI S ,EvANS K, et al. venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia[J]. Blood, 2016,128:1382-1395.
KIM E S, HERBST R S, WISTuBA II, et al. The BATTLE trial: personalizing therapy for lung cancer[J]. Cancer discovery, 2011,1:44-53.
KIM R, EMI M, TANABE K. Cancer immunoediting from immune surveillance to immune escape[J]. Immunology, 2007,121:1-14.
KINGSLEy D P. An interesting case of possible abscopal effect in malignant melanoma[J]. TheBritish journal of radiology, 1975,48: 863-866.
KIvIMAKI M, JOKELA M, NyBERG S T, et al. Long working hours and risk of coronary heart disease and stroke: a systematic review and meta-analysis of published and unpublished data for 603,838 individuals[J]. Lancet, 2015,386: 1739-1746.
KONOPLEvA M, POLLyEA D A, POTLuRI J, et al. Efficacy and Biological Correlates of Response in a Phase II Study of venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia[J].Cancer discovery, 2016,6: 1106-1117.
KROEMER G, GALLuZZI L, KEPP O, et al. Immunogenic cell death in cancer therapy[J]. Annual review of immunology, 2013,31:51-72.
LAN Q, HSIuNG C A, MATSuO K, et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia[J]. Nature genetics, 2012,44:1330-1335.
LARKIN J, CHIARION-SILENI v, GONZALEZ R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in untreated Melanoma[J]. The New England journal of medicine , 2015,373: 23-34.
LEDERMANN J, HARTER P, GOuRLEy C, et al. Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer[J]. The New England journal of medicine, 2012,366: 1382-1392.
LI y, LI y, yANG T, et al. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer[J]. PloS one,2013,8: e52093.
LIN J J, RIELy G J, SHAW A T. Targeting ALK: Precision Medicine Takes on Drug Resistance[J].Cancer discovery, 2017,7: 137-155.
LIN K y, KRAuS W L. PARP Inhibitors for Cancer Therapy[J]. Cell, 2017,169: 183.
Lind S E, Delvecchio Good M J, Minkovitz C S, et al. Oncologists vary in their willingness to undertake anti-cancer therapies[J]. British journal of cancer, 1991,64:391-395.
LO-COCO F, AvvISATI G, vIGNETTI M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia[J]. The New England journal of medicine, 2013,369: 111-121.
MA J L, ZHANG L, BROWN L M, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality[J]. Journal of the National Cancer Institute, 2012,104: 488-492.
MACKIE R M, REID R, JuNOR B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery[J]. The New England journal of medicine, 2003,348: 567-568.
MACKILLOP W J, O’SuLLIvAN B, WARD G K. Non-small cell lung cancer: how oncologists want to be treated[J]. International journal of radiation oncology, biology, physics, 1987,13: 929-934.MAILANKODy S, PRASAD v. Five years of Cancer Drug Approvals: Innovation, Efficacy, and Costs[J]. JAMA oncology, 2015,1: 539-540.
MATuLIS S M, GuPTA v A, NOOKA A K, et al. Dexamethasone treatment promotes BCL-2 dependence in multiple myeloma resulting in sensitivity to venetoclax[J]. Leukemia, 2016,30:1086-1093.
MELLMAN I, NuSSENZWEIG M. Retrospective. Ralph M. Steinman (1943-2011)[J]. Science ,2011,334:466.
MILLER K D, SIEGEL R L, LIN C C, et al. Cancer treatment and survivorship statistics[J]. CA,2016,66:271-289.
MILOWSKy M I, IyER G, REGAZZI A M, et al. Phase II study of everolimus in metastatic urothelial cancer[J]. BJu international, 2013,112: 462-470.
MIRZA M R, MONK B J, HERRSTEDT J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer[J]. The New England journal of medicine, 2016,375：2154-2164.
MIyATA H, TAKAHASHI M, SAITO, et al. Disclosure preferences regarding cancer diagnosis and prognosis: to tell or not to tell? [J]. Journal of medical ethics, 2005,31：447-451.
MOORE S C, LEE I M, WEIDERPASS E, et al. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults[J]. JAMA internal medicine, 2016,176：816-825.
MORICKE A, ZIMMERMANN M, vALSECCHI M G, et al. Dexamethasone vs. prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000[J].Blood,2016,127：2101-2112.
Mu L, LIu L, NIu R, et al. Indoor air pollution and risk of lung cancer among Chinese female non-smokers[J]. Cancer causes & control : CCC,2013,24：439-450.
NAuD P S, ROTELI-MARTINS C M, DE CARvALHO N S, et al. Sustained efficacy, immunogenicity,and safety of the HPv-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination[J]. Human vaccines & immunotherapeutics,2014,10：2147-2162.
NORRIS R E, ADAMSON P C. Challenges and opportunities in childhood cancer drug development[J]. Nature reviews Cancer,2012,12：776-782.
OKAMuRA H, uCHITOMI y, SASAKO M, et al. Guidelines for telling the truth to cancer patients[J]. Japanese journal of clinical oncology ，1998，28：1-4.
OLIvIER M, HOLLSTEIN M, HAINAuT P. Tp53 mutations in human cancers: origins, consequences,and clinical use[J]. Cold Spring Harbor perspectives in biology 2,2010, a001008.
OZA A M, CIBuLA D, BENZAQuEN A O, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial[J]. The Lancet Oncology ，2015,16：87-97.
PARK K, TAN E H, O’ByRNE K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LuX-Lung 7): a phase 2B, open-label,randomised controlled trial[J].The Lancet Oncology ，2016,17：577-589.
PATHAK N, DODDS J, ZAMORA J, et al. Accuracy of urinary human papillomavirus testing for presence of cervical HPv: systematic review and meta-analysis[J]. Bmj ，2014,349：g5264.
PLACE A E, STEvENSON K E, vROOMAN L M, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial[J]. The Lancet Oncology,2015,16：1677-1690.
POSTOW M A, CALLAHAN M K, BARKER C A, et al. Immunologic correlates of the abscopal effect in a patient with melanoma[J]. The New England journal of medicine ，2012,366：925-931.
PuNNOOSE E A, LEvERSON J D, PEALE F, et al. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist venetoclax in Multiple Myeloma Models[J]. Molecular cancer therapeutics ，2016,15：1132-1144.
RECHER C, COIFFIER B, HAIOuN C, et al. Intensified chemotherapy with ACvBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma(LNH03-2B): an open-label randomised phase 3 trial[J]. Lancet,2011,378：1858-1867.
RECK M, RODRIGuEZ-ABREu D, ROBINSON A G, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer[J]. The New England journal of medicine ，2016,375：1823-1833.
RIBAS A, KEFFORD R, MARSHALL M A, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma[J].Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2013,31：616-622.
ROBERTS A W, DAvIDS M S, PAGEL J M, et al. Targeting BCL-2 with venetoclax in Relapsed Chronic Lymphocytic Leukemia[J]. The New England journal of medicine ，2016,374：311-322.ROEMER M G, ADvANI R H, LIGON A H, et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome[J]. Journal of clinical oncology,2016,34：2690-2697.
ROSENBERG S A, PACKARD B S, AEBERSOLD P M, et al. use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report[J]. The New England journal of medicine,1988,319：1676-1680.
ROSS C J, KATZOv-ECKERT H, DuBE M P, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy[J]. Nature genetics,2009,41：1345-1349.
ROWHANI-RAHBAR A, MAO C, HuGHES J P, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine[J]. vaccine ，2009,27：5612-5619.
SCHADENDORF D, HODI F S, ROBERT C, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in unresectable or Metastatic Melanoma[J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015,33:1889-1894.
SHAW A T, ENGELMAN J A. Ceritinib in ALK-rearranged non-small-cell lung cancer[J]. The New England journal of medicine, 2014,370:2537-2539.
SHAW A T, GANDHI L, GADGEEL S, et al. Alectinib in ALK-positive, crizotinib-resistant, nonsmall-cell lung cancer: a single-group, multicentre, phase 2 trial[J]. The Lancet Oncology, 2016,17:234-242.
SHAW A T, KIM D W, NAKAGAWA K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. The New England journal of medicine, 2013,368:2385-2394.
SHI v y, TRAN K, PATEL F, et al. 100% Complete response rate in patients with cutaneousmetastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series[J]. Journal of the American Academy of Dermatology,2015,73：645-654.
SIEGEL R L, MILLER K D, JEMAL A. Cancer Statistics, 2017[J]. CA: a cancer journal for clinicians,2017,67：7-30.
SINGHAL S, MEHTA J, DESIKAN R, et al. Antitumor activity of thalidomide in refractory multiple myeloma[J]. The New England journal of medicine,1999,341：1565-1571.
SLADE B A, LEIDEL L, vELLOZZI C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine[J]. JAMA , 2009,302:750-757.
SMITH T J, DESCH C E, DAvID M, et al. Would oncologists want chemotherapy if they had nonsmall-cell lung cancer? [J]. Oncology, 1998,12: 360,363,365.
SOLOMON B J, MOK T, KIM D W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J]. The New England journal of medicine, 2014,371:2167-2177.
STANGELBERGER A, WALDERT M, DJAvAN B. Prostate cancer in elderly men[J]. Reviews in urology, 2008,10:111-119.
STEINMAN R M. Dendritic cells and vaccines[J]. Proceedings, 2008: 21,3-8.
STINTZING S, FISCHER vON WEIKERSTHAL L, vEHLING-KAISER u, et al. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial[J]. British journal of cancer , 2011,105:206-211.
STOREy A, THOMAS M, KALITA A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer[J]. Nature, 1998,393:229-234.
SuBRAMANIAN J, GOvINDAN R. Lung cancer in never smokers: a review[J]. Journal of clinical oncology , 2007,25: 561-570.
SuN S, SCHILLER J H, GAZDAR A F. Lung cancer in never smokers--a different disease[J]. Nature reviews Cancer, 2007,7: 778-790.
TATTERSALL M H, GATTELLARI M, vOIGT K, et al. When the treatment goal is not cure: are patients informed adequately? [J]. Supportive care in cancer , 2002,10:314-321.
THuN M J, HANNAN L M, ADAMS-CAMPBELL L L, et al. Lung cancer occurrence in neversmokers: an analysis of 13 cohorts and 22 cancer registry studies[J]. PLoS medicine , 2008,5:e185.
uGuREL S, ROHMEL J, ASCIERTO P A, et al. Survival of patients with advanced metastatic melanoma: The impact of novel therapies[J]. European journal of cancer , 2016,53:125-134.
vAN ‘T vEER L J, DAI H, vAN DE vIJvER, et al. Gene expression profiling predicts clinical outcome of breast cancer[J]. Nature, 2002,415:530-536.
vAN MAAREN M C, DE MuNCK L, DE BOCK G H, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands:a population-based study[J]. The Lancet Oncology, 2016,17:1158-1170.
vAN MAELE-FABRy G, LANTIN A C, HOET P, et al. Residential exposure to pesticides and childhood leukaemia: a systematic review and meta-analysis[J]. Environment international,2011,37:280-291.
WAKELEE H A, CHANG E T, GOMEZ S L, et al. Lung cancer incidence in never smokers[J].Journal of clinical oncology, 2007,25:472-478.
WANG S y, CHEN C H, CHEN y S, et al. The attitude toward truth telling of cancer in Taiwan[J].Journal of psychosomatic research , 2004,57:53-58.
WEBER J S, KAHLER K C, HAuSCHILD A. Management of immune-related adverse events and kinetics of response with ipilimumab[J]. Journal of clinical oncology, 2012,30:2691-2697.
WECHSLER M E, KELLEy J M, BOyD I O, et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma[J]. The New England journal of medicine, 2011,365:119-126.
WERSALL P J, BLOMGREN H, PISA P, et al. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma[J]. Acta oncologica,2006,45:493-497.
WHySNER J, MOHAN M. Perineal application of talc and cornstarch powders: evaluation of ovarian cancer risk[J]. American journal of obstetrics and gynecology , 2000,182:720-724.
WILLMAN C L, BuSQuE L, GRIFFITH B B, et al. Langerhans’-cell histiocytosis (histiocytosis X)--a clonal proliferative disease[J]. The New England journal of medicine, 1994,331:154-160.
yANG J C, ROSENBERG S A. Adoptive T-Cell Therapy for Cancer[J]. Advances in immunology,2016,130:279-294.
yOu W C, BROWN L M, ZHANG L LI, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions[J]. Journal of the National Cancer Institute, 2006,98:974-983.
ZARDAvAS D, PICCART-GEBHART M. 2015, Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast Cancer[J]. Am Soc Clin Oncol Educ Book, 2015:e183-190.
ZHANG X W, yAN X J, ZHOu Z R, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML[J]. Science , 2010,328: 240-243.
ZHOu, C. Lung cancer molecular epidemiology in China: recent trends[J]. Translational lung cancer research, 2014,3:270-279.
ZHu H H, QIN y Z, HuANG X J. Resistance to arsenic therapy in acute promyelocytic leukemia[J].The New England journal of medicine, 2014,370:1864-1866.
ZHu H H, Wu D P, JIN J, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial[J]. Journal of clinical oncology , 2013,31:4215-4221.
ZITvOGEL L, APETOH L, GHIRINGHELLI F, et al. Immunological aspects of cancer chemotherapy[J]. Nature reviews Immunology, 2008,8: 59-73.
ZITvOGEL L, RuSAKIEWICZ S, ROuTy B, et al. Immunological off-target effects of imatinib[J].Nature reviews Clinical oncology, 2016,13: 431-446.
ZOu H y, FRIBOuLET L, KODACK D P, et al. PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models[J]. Cancer cell,2015,28:70-81.
方建培，罗学群，等．GZ-2002急性淋巴细胞白血病化疗方案治疗非高危儿童急性淋巴细胞白血病多中心协作临床研究[J]．中国小儿血液与肿瘤杂志，2011，16(2)：60-65.
吴敏媛，等．儿童急性淋巴细胞白血病多中心治疗研究的体会及思考[J]．中华妇幼临床医学杂志，2014，10(3): 269-273.
于洁，张银娟．儿童急性髓系白血病化疗相关进展[J]．中华实用儿科临床杂志，2013,28(15): 1195-1198.
陈静，等．AML-XH-99方案治疗婴幼儿急性髓系白血病临床总结[J]．临床儿科杂志，2012，8: 764-766.
罗学群，等．华南地区儿童急性早幼粒白血病多中心研究中期报告[C]．中国抗癌协会2016大会发言论文，2016.
吴敏媛，等．205例儿童急性淋巴细胞白血病疗效分析[J]．中华血液学杂志，1994，15(5):248.
沈树红，等．上海儿童医学中心急性淋巴细胞性白血病2005方案疗效多中心研究[J]．中华儿科杂志,2013，51(7):495-503